Min Hu1, Murali Gopalakrishnan, Jinhe Li. 1. Neuroscience Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, Illinois 60064-6125, USA.
Abstract
BACKGROUND AND PURPOSE: alpha7-Nicotinic acetylcholine receptors (alpha7 nAChRs) play an important role in cognitive function. Positive allosteric modulators (PAMs) amplify effects of alpha7 nAChR agonist and could provide an approach for treatment of cognitive deficits in neuropsychiatric diseases. PAMs can either predominantly affect the apparent peak current response (type I) or increase both the apparent peak current response and duration of channel opening, due to prolonged desensitization (type II). The delay of receptor desensitization by type II PAMs raises the possibility of Ca2+-induced toxicity through prolonged activation of alpha7 nAChRs. The present study addresses whether type I and II PAMs exhibit different cytotoxicity profiles. EXPERIMENTAL APPROACH: The present studies evaluated cytotoxic effects of type I PAM [N-(4-chlorophenyl)]-alpha-[(4-chlorophenyl)-aminomethylene]-3-methyl-5-isoxazoleacet-amide (CCMI) and type II PAM 1-[5-chloro-2,4-dimethoxy-phenyl]-3-[5-methyl-isoxazol-3-yl]-urea (PNU-120596), or 4-[5-(4chloro-phenyl)-2-methyl-3-propionyl-pyrrol-1-yl]-benzenesulphonamide (A-867744). The studies used cultures of PC12 cells and primary cultures of rat cortical neuronal cells. KEY RESULTS: Our results showed that neither type I nor type II PAMs had any detrimental effect on cell integrity or cell viability. In particular, type II PAMs did not affect neuron number and neurite outgrowth under conditions when alpha7 nAChR activity was measured by Ca2+ influx and extracellular signal-regulated kinases 1 and 2 phosphorylation, following exposure to alpha7 nAChR agonists. CONCLUSIONS AND IMPLICATIONS: This study demonstrated that both type I and type II alpha7 nAChR selective PAMs, although exhibiting differential electrophysiological profiles, did not exert cytotoxic effects in cells endogenously expressing alpha7 nAChRs.
BACKGROUND AND PURPOSE: alpha7-Nicotinic acetylcholine receptors (alpha7 nAChRs) play an important role in cognitive function. Positive allosteric modulators (PAMs) amplify effects of alpha7 nAChR agonist and could provide an approach for treatment of cognitive deficits in neuropsychiatric diseases. PAMs can either predominantly affect the apparent peak current response (type I) or increase both the apparent peak current response and duration of channel opening, due to prolonged desensitization (type II). The delay of receptor desensitization by type II PAMs raises the possibility of Ca2+-induced toxicity through prolonged activation of alpha7 nAChRs. The present study addresses whether type I and II PAMs exhibit different cytotoxicity profiles. EXPERIMENTAL APPROACH: The present studies evaluated cytotoxic effects of type I PAM [N-(4-chlorophenyl)]-alpha-[(4-chlorophenyl)-aminomethylene]-3-methyl-5-isoxazoleacet-amide (CCMI) and type II PAM 1-[5-chloro-2,4-dimethoxy-phenyl]-3-[5-methyl-isoxazol-3-yl]-urea (PNU-120596), or 4-[5-(4chloro-phenyl)-2-methyl-3-propionyl-pyrrol-1-yl]-benzenesulphonamide (A-867744). The studies used cultures of PC12 cells and primary cultures of rat cortical neuronal cells. KEY RESULTS: Our results showed that neither type I nor type II PAMs had any detrimental effect on cell integrity or cell viability. In particular, type II PAMs did not affect neuron number and neurite outgrowth under conditions when alpha7 nAChR activity was measured by Ca2+ influx and extracellular signal-regulated kinases 1 and 2 phosphorylation, following exposure to alpha7 nAChR agonists. CONCLUSIONS AND IMPLICATIONS: This study demonstrated that both type I and type II alpha7 nAChR selective PAMs, although exhibiting differential electrophysiological profiles, did not exert cytotoxic effects in cells endogenously expressing alpha7 nAChRs.
Authors: Raymond S Hurst; Mihaly Hajós; Mario Raggenbass; Theron M Wall; Nicole R Higdon; Judy A Lawson; Karen L Rutherford-Root; Mitchell B Berkenpas; W E Hoffmann; David W Piotrowski; Vincent E Groppi; Geraldine Allaman; Roch Ogier; Sonia Bertrand; Daniel Bertrand; Stephen P Arneric Journal: J Neurosci Date: 2005-04-27 Impact factor: 6.167
Authors: Ke Ren; Viviana Puig; Roger L Papke; Yoshihito Itoh; Jeffrey A Hughes; Edwin M Meyer Journal: J Neurochem Date: 2005-06-22 Impact factor: 5.372
Authors: Alice L Bodnar; Luz A Cortes-Burgos; Karen K Cook; Dac M Dinh; Vincent E Groppi; Mihaly Hajos; Nicole R Higdon; William E Hoffmann; Raymond S Hurst; Jason K Myers; Bruce N Rogers; Theron M Wall; Mark L Wolfe; Erik Wong Journal: J Med Chem Date: 2005-02-24 Impact factor: 7.446
Authors: Peter Curzon; David J Anderson; Arthur L Nikkel; Gerard B Fox; Murali Gopalakrishnan; Michael W Decker; Robert S Bitner Journal: Neurosci Lett Date: 2006-10-20 Impact factor: 3.046
Authors: Donn G Wishka; Daniel P Walker; Karen M Yates; Steven C Reitz; Shaojuan Jia; Jason K Myers; Kirk L Olson; E Jon Jacobsen; Mark L Wolfe; Vincent E Groppi; Alexander J Hanchar; Bruce A Thornburgh; Luz A Cortes-Burgos; Erik H F Wong; Brian A Staton; Thomas J Raub; Nicole R Higdon; Theron M Wall; Raymond S Hurst; Rodney R Walters; William E Hoffmann; Mihaly Hajos; Stanley Franklin; Galen Carey; Lisa H Gold; Karen K Cook; Steven B Sands; Sabrina X Zhao; John R Soglia; Amit S Kalgutkar; Stephen P Arneric; Bruce N Rogers Journal: J Med Chem Date: 2006-07-13 Impact factor: 7.446
Authors: Jane A Dickinson; Katharine E Hanrott; M H Selina Mok; James N C Kew; Susan Wonnacott Journal: J Neurochem Date: 2006-12-20 Impact factor: 5.372
Authors: Morgane Milienne-Petiot; Kerin K Higa; Andrea Grim; Debbie Deben; Lucianne Groenink; Elizabeth W Twamley; Mark A Geyer; Jared W Young Journal: Eur Neuropsychopharmacol Date: 2018-09-11 Impact factor: 4.600